Bone diseases
Follow the links below to find trusted information about bone diseases.
Last reviewed: July 2016
Need more information?
These trusted information partners have more on this topic.
Found 1337 results
Gamma-glutamyl transferase - Lab Tests Online AU
To screen for liver disease or alcohol abuse; and to help your doctor tell whether a raised level of alkaline phosphatase (ALP) is due to liver or bone disease
Read more on Lab Tests Online website
Women's and Children's Hospital, Adelaide
Perthes disease is the name applied to a condition affecting the upper end, or head, of the thigh bone (femur), where it enters into the formation of the hip joint. In this condition, the growing part of the head of the bone goes through a series of changes, in which it softens, breaks up into fragments, and then gradually re-forms. It is not contagious.
Read more on Women's and Children's Health Network website
Knock knees - myDr.com.au
Knock knees (genu valgum) is common in young children. The legs usually straighten as the child grows.
Read more on myDr website
Pagets Disease (formerly Arthritis Victoria) - MOVE
MOVE muscle, bone & joint health (formerly Arthritis and Osteoporosis Victoria) is a national charity dedicated to improve the quality of life of people with, or at risk of developing, muscle, bone and joint conditions.
Read more on MOVE muscle, bone & joint health website
Osgood-Schlatter disease - myDr.com.au
Osgood-Schlatter disease causes knee pain in teenagers. Find out about the causes, symptoms and treatment.
Read more on myDr website
Thyroid disease and osteoporosis
Osteoporosis is a condition in which the bones become fragile, leading to a higher risk of breaks or fractures. A minor bump or fall can be enough to cause a break in someone with osteoporosis. Osteoporosis is more common in people with thyroid conditio ns than in the general population. This factsheet explains how thyroid disease can affect your bones, how to find out if you are at risk of osteoporosis, and what you can do to help protect your bone health
Read more on Osteoporosis Australia website
Brain Foundation | Gaucher Disease
Gaucher Disease Gaucher Disease Read more at Virtual Medical Centre Description Gaucher disease is an inherited illness caused by a gene mutation
Read more on Brain Foundation website
Platelet count - Lab Tests Online AU
As part of a full blood count (FBC) or to diagnose or monitor a bone marrow disorder or blood disease
Read more on Lab Tests Online website
Bone markers - Lab Tests Online AU
Bone Resorption Markers; Bone Formation Markers; Bone Turnover Tests; N-telopeptide; NTx; C-telopeptide; CTx; Deoxypyridinoline; DPD; Pyridinium Crosslinks; Tartrate-resistant Acid Phosphatase; TRAP; Bone-specific Alkaline Phosphatase; Osteocalcin; Procollagen Type 1 N-Terminal Propeptide; P1NP
Read more on Lab Tests Online website
Diagnosis | Osteoporosis Australia
Osteoporosis is diagnosed with a bone density scan (commonly known as a bone density test). It is a simple scan that measures the density of your bones, usually at the hip and spine. You simply lie flat on a padded tableand the arm of the machine passes over your body. The scan takes approximately 10-15 minutes. You remain clothed during the scan. Your GP will first assess your risk factors for osteoporosis before referring you for a test.
Read more on Osteoporosis Australia website
Found 355 results
Interventions for metabolic bone disease in children with chronic kidney disease | Cochrane
Chronic kidney disease (CKD) resulting in reduced kidney function and the need for dialysis and kidney transplant is associated with abnormalities in serum calcium and phosphorus levels leading to high levels of the parathyroid hormone (PTH) and to bone disease. This may result in bone deformities, bone pain, fractures and reduced growth rates. Commonly used treatments (vitamin D compounds and phosphate binders) aim to prevent or correct these outcomes. However, these treatments may raise levels of blood calcium, allow calcium and phosphorus deposition in blood vessels and lead to early cardiovascular disease, which is known to be a problem in adults with CKD.
Read more on Cochrane (Australasian Centre) website
Interventions for preventing bone disease in kidney transplant recipients | Cochrane
Recipients of a kidney transplants have a pre-existing increase in bone fragility resulting from kidney disease. Bone mineral density decreases rapidly in the first year after engraftment and there is continued bone loss through the period of transplantation. The incidence of fracture following successful transplantation is greater than 2% per annum. Bone loss and fracture risk are significantly higher than both the general and dialysis population. This study examines the benefits and risks of treatments used to reduce bone disease following kidney transplantation. Twenty-four trials (12,99 patients) were included. No individual intervention (bisphosphonate, vitamin D sterol or calcitonin) has been shown in randomised controlled trials to reduce fracture risk after kidney transplantation. Meta analysis of all available such trials combined, however, shows that any intervention (bisphosphonate, vitamin D sterol, or calcitonin) for bone disease in kidney transplant recipients does reduce the risk of fracture in this population. These agents also provide a significant improvement in bone mineral density when given after transplantation, although the clinical significance of this is uncertain due to the lack of validation in bone densitometry in chronic kidney disease. Bisphosphonates have greater efficacy to preserve bone mineral density than vitamin D sterols in head-to-head trials.
Read more on Cochrane (Australasian Centre) website
Interventions for bone disease in children with chronic kidney disease | Cochrane
Read more on Cochrane (Australasian Centre) website
Phosphate binders for preventing and treating bone disease in chronic kidney disease patients | Cochrane
People with chronic kidney disease (CKD) develop impaired excretion of the dietary phosphorus. This results in a condition known as mineral and bone disorder in chronic kidney disease (CKD-MBD). CKD-MBD is characterized by high bone turnover, increased musculoskeletal morbidity including bone pain and muscle weakness, and vascular calcification which may contribute to the high incidence of cardiovascular disease and associated deaths. Several agents such as phosphate binders, vitamin D compounds, and calcimimetics are widely used to slow the development and progression of CKD-MBD complications.
Read more on Cochrane (Australasian Centre) website
Bisphosphonate therapy for osteogenesis imperfecta | Cochrane
Read more on Cochrane (Australasian Centre) website
Meditation for adults with haematological malignancies | Cochrane
Cancers of the bone marrow, lymphatic tissue and blood are considered as haematological malignancies. The most common types of haematological malignancies are lymphoma, leukaemia and myeloma but they also include myelodysplastic syndromes or myeloproliferative diseases. Within each type of disease there are various sub-divisions. There are several treatment options depending on the type and severity of the cancer. The most common therapies are chemotherapy, radiotherapy or a combination of both. In some cases, stem cell transplantation is offered (this is where either the patient's own bone marrow cells or cells of another person are implanted in the patient's body after aggressive chemotherapy). Those suffering from haematological cancers may have serious symptoms, and treatments often cause severe and distressing side effects.
Read more on Cochrane (Australasian Centre) website
Alkylating agents for Waldenstrom's macroglobulinaemia | Cochrane
Waldenstrom's macroglobulinaemia (WM) is an uncommon B-cell lymphoproliferative disorder characterised by bone marrow infiltration and production of monoclonal immunoglobulin. It is a kind of non-Hodgkin's lymphoma which can lead to death. Alkylating agents are believed to be effective in treatment of Waldenstrom's macroglobulinaemia for alleviating symptoms and elongating survival time. The review authors found one randomised controlled trial with 92 participants that considered fludarabine was superior to the alkylating agents-containing regimen for pretreated/relapsed patients with Waldenstrom's macroglobulinaemia.
Read more on Cochrane (Australasian Centre) website
Are changes to diet effective to manage mineral and bone abnormalities in people with chronic kidney disease? | Cochrane
Are changes to diet effective to manage mineral and bone abnormalities in people with chronic kidney disease?
Read more on Cochrane (Australasian Centre) website
Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease | Cochrane
Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease
Read more on Cochrane (Australasian Centre) website
Processed versus fresh frozen bone for repairing the bone in revision hip surgery | Cochrane
This summary of a Cochrane review presents what we know from research about the advantages and disadvantages of using fresh frozen bone or processed bone for repairing the hip bone during surgery.
Read more on Cochrane (Australasian Centre) website
